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Directions for new developments on
statistical design and analysis of small
population group trials
Ralf-Dieter Hilgers1*† , Kit Roes2†, Nigel Stallard3† and for the IDeAl, Asterix and InSPiRe project groups
Abstract
Background: Most statistical design and analysis methods for clinical trials have been developed and evaluated
where at least several hundreds of patients could be recruited. These methods may not be suitable to evaluate
therapies if the sample size is unavoidably small, which is usually termed by small populations. The specific sample
size cut off, where the standard methods fail, needs to be investigated. In this paper, the authors present their view
on new developments for design and analysis of clinical trials in small population groups, where conventional
statistical methods may be inappropriate, e.g., because of lack of power or poor adherence to asymptotic
approximations due to sample size restrictions.
Method: Following the EMA/CHMP guideline on clinical trials in small populations, we consider directions for
new developments in the area of statistical methodology for design and analysis of small population clinical
trials. We relate the findings to the research activities of three projects, Asterix, IDeAl, and InSPiRe, which have
received funding since 2013 within the FP7-HEALTH-2013-INNOVATION-1 framework of the EU. As not all aspects
of the wide research area of small population clinical trials can be addressed, we focus on areas where we feel
advances are needed and feasible.
Results: The general framework of the EMA/CHMP guideline on small population clinical trials stimulates a
number of research areas. These serve as the basis for the three projects, Asterix, IDeAl, and InSPiRe, which use
various approaches to develop new statistical methodology for design and analysis of small population clinical
trials. Small population clinical trials refer to trials with a limited number of patients. Small populations may result
form rare diseases or specific subtypes of more common diseases. New statistical methodology needs to be
tailored to these specific situations.
Conclusion: The main results from the three projects will constitute a useful toolbox for improved design and
analysis of small population clinical trials. They address various challenges presented by the EMA/CHMP guideline
as well as recent discussions about extrapolation. There is a need for involvement of the patients’ perspective in
the planning and conduct of small population clinical trials for a successful therapy evaluation.
Keywords: EMA/CHMP Guideline on clinical trials in small populations, Statistical methods, Statistical design,
Statistical analysis, Small population clinical trials, Rare disease
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Background
Most statistical design and analysis methods for clinical
trials have been developed in the setting of confirmatory
trials with relatively large sample sizes, perhaps several
hundreds or even thousands of patients. These methods
may not be suitable to evaluate therapies in small popu-
lations, for example when the size of the population is
limited because a disease is rare, or a treatment is tar-
geted at a particular genetic subgroup or a small paediat-
ric population. Such cases, where there is a limited
number of patients that could potentially be enrolled in
the trial, raise a number of specific statistical challenges
and can lead to slow approval of orphan drugs for mar-
keting and poorly designed studies [1].
The Asterix, IDeAl and InSPiRe projects
In the light of these challenges, in 2013 the European
Commission set up a unique call for new methodologies
for clinical trials for small population groups within the
FP7-HEALTH-2013-INNOVATION-1 [2] framework.
This builds on other initiatives from around the world
aimed at improving research, including methodology, in
rare diseases [3]. The objective of the research is to de-
velop new or improved statistical methodologies for clin-
ical trials for the assessment of treatments for small
population groups, in particular for rare diseases or perso-
nalised (stratified or individualised) medicine. Research is
expected to be multidisciplinary and should involve all
relevant stakeholders including industry and patient advo-
cacy groups as appropriate.
Three collaborative research projects Asterix, IDeAl,
and InSPiRe, are funded under this call. As illustrated in
Figs. 1, 2 and 3, the three projects focus on a number of
methodological challenges in the design, analysis and in-
terpretation of clinical trials in small populations and
rare diseases as well as considering specific aspects such
as patient perspectives and ethical issues.
Regulatory guidance
In the EU, a disease is defined as rare if the prevalence is
not more than 5 in 10,000. New drug treatments for
these rare diseases may be eligible for orphan drug des-
ignation, also depending on other conditions – such as
the status of existing treatments. The number of rare
diseases is estimated to be around 7000 [4]. Thus al-
though the diseases themselves are rare, the total num-
ber affected in the EU is estimated to exceed 30 million
[5] with 6 % of the global population affected by a rare
disease at some stage in their life [6], resulting in consider-
able total health care cost [7]. More than 1120 orphan
drug designations have been granted by the EMA since
2000, and 114 orphan drugs received market authorization
by January 2016 [8]. This seem to be small compared to
the objective of the international rare disease research
consortium to develop 200 new therapies by 2020 [9]. Al-
though many factors complicate the development of new
medicines for orphan diseases, the main issue setting it
apart from drug development for common diseases is the
challenge of generating acceptable evidence from clinical
trials in the clinical research phase in which recruitment is
necessarily limited.
In the EU clinical trials in drug development for small
population groups should take into account the EMA/
CHMP guideline [10] together with a recently published
reflection paper on extrapolation of efficacy and safety in
medicine development [11]. In the US the FDA drafted
guideline on orphan drug approval has been published
[12], whereas in Japan no such specific guidance for clin-
ical trials in small populations exists. To summarize, the
EMA/CHMP guideline states, that “No methods exist that
are relevant to small studies that are not also applicable to
large studies. However, it may be that in conditions with
small and very small populations, less conventional and/or
less commonly seen methodological approaches may be
acceptable if they help to improve the interpretability of
the study results” [10]. Further it is recommended to use
as much information as possible for designing a clinical
trial and extract as much information as possible from a
clinical trial to enable valid benefit risk assessment. Add-
itionally the EMA/CHMP guideline [11] suggests avoiding
unnecessary clinical trials e.g., by extrapolation from a lar-
ger source population to a smaller target population when
this is appropriate.
Paper outline
This paper is structured around the headings in the
EMA/CHMP guideline [10]; “Levels of evidence”,
Fig. 1 Asterix approach to advance trial design in small populations
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“Pharmacological considerations”, “Choice of endpoints”
and “Methodological and statistical considerations”. We
add “extrapolation” and “patient involvement and ethical
considerations” as additional points, but do not consider
specifically “Choice of control groups” except when this
arises in association with the other headings. Under each
heading we give a brief overview of the key statistical
and methodological challenges and explain how the
three EU funded projects Asterix, IDeAl, and InSPiRe
address these challenges and will stimulate uptake of
new methodology in practice. Some further aspects will
be considered, where we feel that extensions are helpful,
e.g., taking into account health economic aspects.
Biostatistical Research by Asterix, IDeAl and
InSPiRe
Levels of evidence
The EMA/CHMP guideline states that, as a general rule,
the same standards of levels of evidence are to be ap-
plied to applications for marketing authorisations in
small populations as are used for other products. The
usual hierarchy of evidence places evidence from ran-
domised controlled trials, either individual trials or
meta-analyses of trials, as being of the highest quality.
Conventionally, sample sizes for definitive randomised
controlled trials are large and in some small population
settings, particularly in very rare diseases, such trials
Fig. 2 Exhibit of the IDeAl project broken down in the workpackages
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may be infeasible. The guideline indicates that the
limitation on patient recruitment in a small population
setting will be taken into account. The level of evi-
dence required might thus partly be determined by the
potential availability of evidence, with decisions taken
accordingly. From a regulatory perspective, exceptions
from the default licensing requirements are considered
in the interest of patients’ access to treatments. ‘Marketing
Authorisation under Exceptional Circumstances’ permits
licensing under greater than usual uncertainty when a
‘comprehensive clinical evidence base’ is not achievable.
This, however, leads to case-by-case decision making,
which makes planning for prospective drug development
strategies more difficult, and hampers adhering to the
same standard. Hence, providing a more quantitative
foundation for the level of evidence applied is an import-
ant challenge. This will be addressed by the research of
the Asterix, IDeAl and InSPiRe projects as follows:
 An approach will be developed based on
Bayesian decision theory to obtain optimised
clinical trial designs that account for prior belief
regarding the benefits of treatment and the
population size.
 Methods to relax the traditionally applied levels of
type 1 and type 2 errors based on the anticipated
finite (and relatively small) future population to treat
will be developed, essentially based on a mix of
Bayesian and frequentist methods.
 Value of information methods will be applied to
assess appropriate sample sizes for clinical trials in
small populations.
 In small clinical trials properties of randomization
procedure relying on approximate arguments fail to
suffice. Recommendations for selection of the best
practice randomization procedure maintaining the
significance level in the presence of selection bias
will be derived.
 Determination of appropriate levels of evidence for
decision-making in small population clinical trials
will be investigated.
When evidence from randomised controlled trials is
limited or absent, evidence from lower levels in the hier-
archy, including observational studies or case-reports, may
become of greater importance together with systematic re-
view and synthesis of all available information, whatever its
source. The formal synthesis of evidence from sources of
differing quality, briefly evidence synthesis, using either
Bayesian or frequentist meta analysis methods, can present
particular statistical challenges.
This challenge will be addressed by the research of the
Asterix, IDeAl, and InSPiRe projects in the following
ways:
 Evidence synthesis methods for small populations
and rare diseases will be developed to support the
planning, analysis and interpretation of a single
randomised controlled trial. The feasibility and
utility of the newly developed methods will be
assessed in small population settings.
 Generalized evidence synthesis approaches will be
applied to paediatric studies and compounds
developed for potentially multiple rare indications.
 Evidence synthesis methods across trials (of similar
or different design) that take into account the
sequential nature of drug development will be
developed.
Fig. 3 Exhibit of the InSpiRe project broken down in the work packages
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Pharmacological considerations
The “pharmacological considerations” section of the
EMA/CHMP guideline suggests that the design of a
clinical trial could be improved by detailed pharmaco-
logical knowledge of the disease and the drug under
consideration [13]. As elaborated in the guideline,
knowledge about the variability is essential for efficient
study design and use of the best available techniques to
obtain and analyse information is crucial. It is well
known that poor designs may be a unnecessary source
of variation.
Many drugs are metabolized in a nonlinear e.g., expo-
nential fashion. Thus the description of pharmacological
processes needs the application of complex statistical
models, such as non-linear mixed effects models. These
models allow the evaluation of drug profiles resulting
from repeated drug concentration measurements from a
group of patients while considering individual variation.
As these models are extensions of the usual linear mixed
effects models, they are nonlinear in the parameters
to be estimated, which complicates the optimal design
problem.
These aspects will be addressed by the research in the
Asterix, IDeAl, and InSPiRe projects in the following
way:
 Pharmacometric [14] approaches will be considered
by modelling the disease – therapy relation using
non-linear mixed effect models. These theoretical
models are used for improved sample size estimation
in small clinical trials allowing for uncertainty, defin-
ing appropriate outcome measures and investigating
analysis methods.
 Optimal design techniques, resulting in time points
of observation based on minimization of the
variance of the effects estimators in nonlinear
mixed-effects models will be developed by means of
using preliminary estimates from interim looks to
improve the final estimator. New numerical
techniques in case of small samples where asymptotic
assumptions are no longer valid.
 Innovative designs for early phase clinical trials
taking into account safety, efficacy and
pharmacokinetic/pharmacodynamic (PK/PD)
measures will be developed to better estimate the
dose level to be recommended based on limited
sample sizes and subgroups with continuous and
binary outcomes.
 The performance of the novel methods will be
evaluated in terms of information gain, number of
subjects, efficiency, and robustness. Designs for
within patient data modelling will be developed to
allow as much information as possible to be used for
benefit risk assessment.
 Improved methods for identification of genetic
prognostic factors will be derived, leading to efficient
clinical trial design and analysis.
Choice of endpoints
The EMA/CHMP guideline indicates that although hard
clinical endpoints, such as survival or serious mobidity,
are preferred, surrogate endpoints may be an option in
small populations clinical trials [10] although evaluation
of the surrogates might be challenging [15]. Another dir-
ection in particular in small clinical trials is to use end-
points from medical care which are important for the
patients, briefly patient-centered endpoints [16], e.g.,
where hard clinical endpoints (such as survival) cannot
be observed in sufficient patients within a reasonable
timeframe. This implies further challenges like showing
the clinical relevance of the patient-centered endpoint,
capacity to measure the risk-benefit relation and reliabil-
ity considerations. On the other hand, the problem of
how to derive a uniform definition of a patient-centered
endpoint has not yet been solved. Due to clinical hetero-
geneity of the disease course in many rare diseases, pa-
tients’ need for improvement can vary substantially with
respect to outcome measure. Although patient involve-
ment in the definition of outcomes is high on the agenda
of public funders, regulators and international research
groups [17, 18], many generic measurement instruments
for patient-centered outcomes may not be sufficiently re-
sponsive to detect changes for a particular disease. Fur-
ther, the primary analysis of most confirmatory clinical
trials relies on a single primary endpoint, which does
not reflect the need to use as much information as pos-
sible in particular in small clinical trials where typically a
range of relevant outcome measures describes the bene-
fit/risk of a treatment. Making use of this information
may improve efficiency by capturing heterogeneity
between patients’ disease courses. Related to this is the
heterogeneous and multivariate nature of the disease
course, where it may not be obvious which aspects are
actually affected by treatment or need priority. These is-
sues will be addressed in the three EU funded projects
as follows:
 A suitable framework for validation of
biomarkers as surrogate endpoints in small
clinical trials will be developed and optimal
designs investigated. Hereby, the most
appropriate approach, e.g., the causal inference
and meta analytical paradigm will be evaluated
within the context of small samples.
 The impact of unbalanced small data sets on
numerical accuracy for mixed effects models used
for surrogate endpoint validation will be
investigated.
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 Recommendations for models to describe the
reliability of measurements in longitudinal
studies, where the number and measurement
times differs between subjects and the number of
longitudinal measurements is large compared to
the number of subjects of the trial will be
established.
 The possibility of using an individualized outcome
measurement instrument, called Goal Attainment
Scale [19], will be investigated. This may enable
generation of evidence in diseases for which patient
variability precludes the use of conventional
variables to demonstrate efficacy.
 Strategies will be developed that use information
from multiple endpoints to make inference on
treatment benefit [2, 14, 20–23].
Methodological and statistical considerations
The section on “Methodological and statistical consider-
ations” in the EMA/CHMP guideline covers “design
stage,” “data analysis,” and “reporting”. Here it is stated
that the sources of variation should be reduced by using
efficient designs and the variation should be explained
by adequate statistical models. Elements of this, such as
the choice of the endpoint and incorporation of ex-
ploratory factors in the statistical model, have implica-
tions on the precision of the treatment effect estimate
and the optimal design choice. General approaches
taken to address these issues in the three EU funded
projects include:
 Specific designs which are recommended in small
population clinical trials will be evaluated
concerning, whether it is possible to estimate the
treatment effect without bias.
 Once the treatment estimate could be estimated
without bias, optimal designs minimizing the
variation of the estimates, e.g., in non-linear mixed
effects models to analyse data in small population
groups will be derived.
Randomisation is a key element in designing a clinical
trial in particular to avoid bias. Matching and stratification
are mentioned in the EMA/CHMP guideline as options
to improve the power, but the effectiveness of stratified
randomisation in small clinical trials is questionable. A
particular challenge in rare diseases, where recruitment
times can be prolonged, are time trend biases that can
occur if patients’ response to treatments change over
time in some systematic way. Further, selection bias
could invalidate study results even in double blind trials,
where blinding is subverted by observing adverse events
[24]. These problems are more relevant in small clinical
trials where restricted randomisation methods are
favored by scientists and long run arguments may be in-
valid. The three EU funded projects will address the fol-
lowing objectives:
 The impact of selection and time trend bias on
the validity of trial results depending on the
selected randomisation procedure will be
investigated and recommendations derived for
different endpoints such as continuous or time
to event.
 A framework for scientific arguments to select the
“best” randomisation procedure reflecting the
practical clinical constraints will be derived.
 A bias corrected randomisation test will be
developed.
 The advantage of covariate or stratified
randomisation procedures in small population
clinical trials will be examined.
 The benefits and limitations of response adaptive
randomisation in small population clinical trials will
be evaluated.
Options for efficient clinical trial design are adaptive
or sequential approaches in which data are evaluated at
a series of interim analyses used to stop or modify the
remainder of a clinical trial [25]. Within this context the
three EU funded projects will address the following
questions:
 Adaptive designs such as multi-arm multi-stage tri-
als suitable for small populations will be developed.
 Modelling and extrapolation tools will be
incorporated in adaptive designs for confirmatory
studies.
 Adaptive designs that take into account multiple
endpoints, biomarkers or surrogate endpoints
efficiently will be developed.
 The use of adaptive designs within a trial will be
compared with the use of adaptive strategies across
trials in a drug development programme.
 The use of adaptive estimation in non-linear mixed
effects models to gain in precision and sample size
will be explored.
 The extent of bias due to interim analysis will be
investigated.
Special types of study designs are needed if very few
patients are affected or if individualised therapies should
be evaluated. For instance, the EMA/CHMP guideline
includes a discussion of n-of-1 trials, a study design
which has found little attention in large population tri-
als. In such trials the patient receives a series of treat-
ments preferably selected in random order for a chronic
disease that quickly return to stable baseline values after
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treatment. These aspects are addressed in the three re-
search projects:
 Pharmacogenetic information for tailored
therapeutics including its application in crossover
trials, n-of-1 trials and enrichment trials will be
investigated.
 Randomisation and bias arguments for the validity
of n-of-1 trials will be elaborated and randomisation
based inference will be developed.
Aspects of data analysis mentioned in the EMA/
CHMP guideline include the distributional assumptions
required in the analysis of small clinical trials. The un-
satisfactory restriction to use only descriptive statistical
methods for analysis of small clinical trials [26] is in
contrast to the high amount of information often result-
ing from longitudinal observations in small clinical trials.
Non-parametric analysis and/or statistical modelling of
longitudinal data may serve as tools for improved statis-
tical analysis. As the EMA/CHMP guideline states, such
methods “while not relying on strong distributional as-
sumptions should be considered and may be preferred
compared to parametric statistical approaches when as-
sumptions justifying a population based inference are
questionable.” The three EU funded projects will address
these points as follows:
 The use of randomisation-based inference in small
clinical trials, where asymptotic behaviour of
parametric tests is questionable will be evaluated. In
particular, randomisation tests for complex statistical
models and response adaptive randomisation
procedures will be developed
The guideline recommends using prognostic factors as
stratification factors in the randomisation and analysis in
order to minimize the variance of treatment effect esti-
mates. This consideration leads to the following objec-
tives in the three EU funded projects:
 The gain in efficiency of stratification in small
clinical trials will be investigated.
 The use of non-linear and linear mixed effects
models for longitudinal, hierarchical, and clustered
data in small data sets and for unbalanced data will
be considered. In particular, non- or semi-
parametric methods that do not rely, or rely less, on
asymptotic arguments will be developed.
 More complex models that include genetic factors
that influence the response to therapy in small
population groups will be studied.
 Longitudinal data analysis methods will be improved
with respect to non-parametric methods to
overcome potential weaknesses caused by the
asymptotic theory.
 Frequentist and decision theoretic methods will be
developed to predict patients’ responses to targeted
treatments based on genetic features or other
biomarkers enabling subgroups of patients for which
the benefit risk balance of a treatment is positive to
be identified and confirmed.
Bayesian methods, in particular Bayesian designs, may
be effective in small clinical trials and lead to increased
acceptance in the context of evaluation of medical de-
vices [27]. Certainly FDA has approved some devices for
orphan indication based on use of informative priors.
However, the introduction of prior belief is often a concern
in therapy evaluation. Bayesian ideas may also be used for
decision analysis. This requires a multi-disciplinary ap-
proach. Such methods are often used in health technology
assessment, although the evaluation criteria may vary sig-
nificantly. The three EU funded projects will address these
challenges as follows:
 The decision analysis framework will be expanded
by explicitly studying the inter-relationship
between the decision analyses made by health
technology assessors, regulators, patients and trial
sponsors.
 The way in which decision analysis affects the
design of a clinical trial will be evaluated.
Extrapolation
As already stated, clinical trials in small populations are
challenging because of the limited number of patients
that can be enrolled. One way out of the limitations may
be to attempt to extrapolate from clinical trials of similar
treatments or of the same treatment in other diseases or
larger population groups. It may be helpful for example
if a drug is already in use for a more common disease
[28] and for diseases that are rare in the EU but more
common in other continents. Another aspect of extrapo-
lation concerns the modelling of dose response informa-
tion by the transfer of knowledge from larger to smaller
populations so that it is possible to avoid unnecessary
studies [11]. This is reflected by the following objectives
of the three EU-funded projects:
 The uncertainty in dose–response information when
knowledge of disease and drug is used to extrapolate
from a large population to a much smaller target
population will be quantified.
 The use of extrapolation within a Bayesian
framework will be explored.
 Adaptive design strategies for extrapolation studies
will be considered.
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 Guidance on the data to include in registries to
support extrapolation and control group data for
trial design will be developed.
Patient involvement and ethical considerations
Including the patient perspective into the design of tri-
als is of general interest. Arguably it is even more
needed in rare diseases, for which there is an urgent
need for the development of new treatments, than in
more common diseases for most of which some type of
treatment is already available. Patients and their repre-
sentatives are in a crucial position to influence the will-
ingness to participate in clinical trials. There is no
consensus on the best practice of involving patients or
patient representatives in the design phase of a trial, let
alone a series of trials. In the case of rare diseases this is
complicated by the small number, geographical spread
and possible clinical heterogeneity of the available par-
ticipants in such a pre-trial design process. However,
the level of patient involvement is usually high – par-
ticularly in rare diseases there are many patient repre-
sentation organizations (in the Orphanet database over
2500 patient organizations in Europe are registered,
with over 500 operating at an international level). The
three EU funded projects will address the questions in
the following ways:
 A “Patient Think Tank” is established within one
of the projects to directly involve the patient
voice in a project and to work together on
models for patient involvement in design stages
of a trial. Patient organizations are represented
in this Think Tank.
 Involvement of patients at the design stage is also
aimed to assess impact of design features (such as
assessment schedules, informed consent procedures,
multiple treatment arms) on willingness and ability
to participate.
Since research in rare diseases primarily remains re-
search with human research subjects, the common frame-
work for ethically evaluating clinical research equally
applies to studies with small populations. Innovative trial
designs in rare diseases may yield new ethical questions
that have to be addressed, such as how we should balance
scientific validity and reliability of evidence for favourable
benefit-risk ratio. Another example is that informed con-
sent processes may differ if innovative designs like adap-
tive trials are used [29]. For instance, one may ask
whether participants should be able to understand that
those who enter an adaptive trial later may have a higher
chance of receiving the more favourable treatment.
Research questions addressed by the three EU funded
projects will include:
 To what extent does our ethical framework need to
be adjusted to accommodate using innovative trial
designs in the context of research on orphan
diseases?
 Could we ethically accept less stringent standards of
evidence in the context of rare diseases in order to
benefit people with orphan diseases sooner?
Ethical perspectives are reflected in the projects in par-
ticular in the extended advisory boards. In answering these
questions, the framework of Emmanuel [30] is used as
starting point.
Regulatory impact and dissemination
For regulatory impact it is essential that specific guid-
ance can be given on the use and acceptability of new
methods. This is where the current guidance may fall
short. As there are several thousands of rare diseases de-
velopment of disease specific guidelines is impractical.
To support regulator impact we propose an intermediate
approach based on clustering of diseases sharing similar
characteristics that determine similar methodological ap-
proaches to their study. While previous approaches have
focused on the selection of the best design for a single
disease, through algorithms guided on disease and treat-
ment characteristics [31, 32], the aim of our clustering is
wider, in the sense of serving as the framework to pro-
duce methodological and regulatory recommendations
that can be valid not only for a single study or disease,
but for the general approach to product development of
a group of diseases sharing similar traits.
Awareness of biostatistical methods
A major goal of all three projects is to raise awareness
and to disseminate newly developed statistical methods
throughout the scientific community involved in clinical
research. We will undertake dissemination activities such
as teaching relevant groups and informing the scientific
community and general public about the project through
our websites (www.asterix-fp7.eu, www.ideal.rwth-
aachen.de, www.warwick.ac.uk/inspire). We will publish
our findings in peer-reviewed journals and stimulate
the process of revision or development of regulatory
guidelines as necessary. Information about the newly
developed results will be targeted towards all relevant
groups, e.g., regulators, patient advocacy groups, industry,
the scientific community, etc. Further dissemination activ-
ities will include giving information about our methods to
patient, families, carers, clinicians, social services, regula-
tors, etc., and training of early stage researchers and other
interested parties. Results are discussed on a regular basis
with the projects’Advisory Boards that include representa-
tives from EMA, eurordis and patient organisations,
amongst others. Although funding is organised around
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three projects, the scientists involved collaborate closely
to ensure that work progresses efficiently and without du-
plication. Some pairs of projects have members in com-
mon, as do project advisory boards, and representatives of
the three projects meet regularly at conferences and scien-
tific meetings, where current and planned research direc-
tions are presented and discussed. In some cases, this has
led to closer links between projects with groups compris-
ing scientists from more than one of the funded projects
collaborating on a specific topic.
Conclusion
The three projects address open statistical methodo-
logical design and analysis problems for clinical trials in
small population groups, encompassing areas like rare
diseases in paediatrics, nephrology, etc. and as well as
subgroups of populations, and individualised therapy
evaluation.
The description above shows the wide spread and
interwoven structure of the research, which has to be
addressed. Obviously, additional research will be stimu-
lated by the investigations. The main gain will be that
new methods are available with proven efficiency for
small population clinical trials. The derived methods will
serve as a basis for small population clinical trials in the
future.
This paper aims to raise awareness of the ongoing re-
search and stimulate other groups to work on statistical
methodology on design and analysis of clinical trials in
small populations. Having well informed researchers,
physicians and biostatisticians will result in the use of
more efficient methods to conduct a clinical trial in
small population groups and thus bring approved treat-
ments faster to our patients.
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